Diagnosis Promise and Limitations of Molecular Skin Cancer

Author(s): Ankit Gupta

A substantial and growing worldwide health burden is skin cancer. The existing diagnostic method has some noteworthy shortcomings, while being robust and capable of producing clinically useful data. In order to make an accurate diagnosis utilising standard skin cancer diagnostics, a patient's access to this workflow may be constrained by their location or unforeseeable circumstances, such coronavirus illness. In oncology, the use of molecular biomarkers has revolutionised diagnosis and therapy. Rapid advances in molecular biology techniques have expanded our understanding of the molecular mechanisms that underlie cancer pathologies and produced biomarkers that may be used to track the progression of malignant illnesses. The commercially available, clinically verified, and developing molecular biomarkers for skin cancer are covered in this article. What makes a perfect molecular biomarker are outlined. In order to develop a future model of molecular biomarker skin cancer diagnostics, the possible advantages and disadvantages of implementing molecular biomarker tests throughout the course of skin cancer from susceptibility through therapy are addressed. Skin cancer is a growing global public health problem despite rising survival rates. Significant negative effects on patients' morbidity and quality of life also result from skin cancer's high economic expense. Because skin cancer causes such a major disease burden, it is crucial to develop accurate and affordable diagnostics. In the US, skin cancer costs the national health care system $8 billion USD yearly between.